Tumors characterized by co-expression of S100 and CD34, in the absence of SOX10, remain difficult to classify. Triggered by a few index cases with monomorphic cytomorphology and distinctive stromal and perivascular hyalinization, immunopositivity for S100 and CD34, and RAF1 and NTRK1 fusions, the authors undertook a systematic review of tumors with similar features. Most of the cases selected were previously diagnosed as low-grade malignant peripheral nerve sheath tumors, while others were deemed unclassified. The tumors were studied with targeted RNA sequencing and/or FISH. A total of 25 cases (15 adults and 10 children) with kinase fusions were identified, including 8 cases involving RAF1, 2 BRAF, 14 NTRK1, and 1 NTRK2 gene rearrangements. Most tumors showed a monomorphic spindle cell proliferation with stromal and perivascular keloidal collagen, in a patternless architecture, with only occasional scattered pleomorphic or multinucleated cells. Most cases showed low cellularity, a low mitotic count, and absence of necrosis. Although a subset showed overlap with lipofibromatosis-like neural tumors, the study group showed distinctive hyalinization and overt malignant features, such as highly cellular fascicular growth and primitive appearance. All tumors showed co-expression of S100 and CD34, ranging from focal to diffuse. SOX10 was negative in all cases. NTRK1 immunohistochemistry showed high levels of expression in all tumors with NTRK1 gene rearrangements. H3K27me3 expression performed in a subset of cases was retained. These findings together with the recurrent gene fusions in RAF1, BRAF, and NTRK1/2 kinases suggest a distinct molecular tumor subtype with consistent S100 and CD34 immunoreactivity.
ambiguous immunoprofile, such as tumors co-expressing S100 protein and CD34, in the absence of SOX10 reactivity. Prompted by detection of RAF1 and NTRK1 fusions in a group of tumors with monomorphic cytomorphology and co-expression of S100 and CD34, somewhat reminiscent of low-grade malignant peripheral nerve sheath tumors (MPNST), we mined our pathology department and consultation files at the contributing institutions for additional similar cases. Using a number of complementary molecular methods for fusion discovery and detection, including targeted RNA sequencing and FISH, we undertook a detailed pathologic characterization of a group of tumors sharing gene rearrangements in RAF1, BRAF, NTRK1, and NTRK2, which were previously labeled as MPNST or placed in the unclassified spindle cell sarcoma category.
| MATERIALS AND METHODS

| Cases
The study was triggered by 2 index cases with RAF1 or NTRK1 fusions which showed similar morphologic features and an identical immunoprofile of S100 and CD34 positivity. Thus the selection criteria were based on the light microscopic features of these index cases showing uniform spindle cell phenotypes with patternless architecture and band-like, keloidal stromal, and perivascular deposition of compact collagen. An immunoprofile of S100/CD34 coexpression, while lacking SOX10 staining, was also required for inclusion in the series. Using these strict criteria, a series of 20 cases of predominantly monomorphic, spindle cell tumors were selected from our archival and consultation files. Database searches were performed focusing on a previous diagnosis of lowgrade or intermediate-grade MPNST or unclassified atypical/lowgrade spindle cell tumors with co-expression of S100 and CD34 markers. Three additional cases were identified based on the presence of a kinase fusion positive result, and subsequently included in the series as showing a similar morphologic spectrum and immunoprofile. An H3K27me3 was performed in a subset of cases with increased cellularity, mimicking MPNST. All confirmed cases had material for further molecular investigation. Medical charts were reviewed when available to exclude a history of NF1. Prototypical high-grade sarcomas or high-grade MPNSTs with high mitotic count, geographic areas of necrosis, and loss of H3K27me3 were excluded, as were MPNST cases associated with NF1 or previous radiation. A high-power field (HPF) was defined at ×400 magnification (0.237 mm 2 field of view) using an Olympus BX51 microscope (Olympus, Tokyo, Japan) with a standard eyepiece of 22 mm diameter. None of the tumors showed evidence of a pre-existent benign peripheral nerve sheath tumor.
| Immunohistochemistry
Immunohistochemistry for CD34, S100, and SOX10 expression was performed in all selected cases, using previously described method. 2 In tumors with NTRK-related fusions, IHC staining for TrkA (NTRK1) was performed on 12 of the 14 NTRK1-rearranged tumors, mostly in retrospect after the identification of the positive results by FISH/RNA sequencing. We used a commercially avail- and analyzed by STAR-Fusion.
| Anchored multiplex RNA sequencing (Archer DX)
One case was studied by Anchored Multiplex RNA sequencing assay, the detailed procedure of which has been previously described. 9 Unidirectional gene-specific primers were designed to target specific exons in 62 genes known to be involved in oncogenic fusions in solid tumors. In brief, RNA was extracted from formalin-fixed paraffinembedded (FFPE) specimens, followed by cDNA synthesis and library preparation. Anchored Multiplex polymerase chain reaction amplicons were sequenced on Illumina Miseq, and the data were analyzed using the Archer software. 2) . However, the tumors in this genetic group spanned a morphologic spectrum. At one end of the spectrum were tumors with atypical or low-grade features, characterized by low cellularity, mostly monomorphic cytology, and low mitotic activity.
| Fluorescence in situ hybridization
At the opposite end of the spectrum were cases with an overtly malignant phenotype, showing marked increased cellularity, moderate increased mitotic activity, but lacked necrosis. Six RAF1/BRAF rearranged tumors had pure low-grade morphology with low cellularity and abundant collagenous stroma, and a low mitotic count (1-2 MF/10 HPFs) and lacked necrosis. One tumor each with RAF1/BRAF gene abnormalities (case 1 and 10) showed hybrid morphology, with low-grade areas that were mostly sharply demarcated from areas of increased cellularity and fascicular growth (Figures 1 and 2 ). The Follow-up was available in 6 of the 10 cases. Among the 6 cases with low cellularity/pure low-grade tumors, follow-up was available in half of them; 2 patients were with no evidence of disease (NED) and 1 had persistent local disease in the hand after 22 months follow-up (case 9), as it was originally excised with positive margins (Table 1) .
From the 4 cases with malignant phenotype (increased cellularity and mitotic activity), follow-up was available in 3 cases, showing 2 patients with NED after 9 and 25 months, respectively. The latter patient (case 8) had an initial incomplete resection, followed by re-excision and radiation therapy. The third patient (Case 1), a 67-year-old female with a large 15 cm upper intra-abdominal mass, infiltrating stomach and pancreas, developed numerous lung, liver, and intraperitoneal metastases and was alive with disease after 7 months follow-up. This 3.3 | NTRK-rearranged spindle cell tumors encompass a histologically diverse spectrum spanning low and high cellularity
There were 14 tumors with NTRK1 rearrangements and one with NTRK2-related fusion (Table 1) . Eight NTRK1-rearranged tumors presented in pediatric patients younger than 18 years of age (range 3-17, mean 11.3), whereas six tumors occurred in adults (age range The most common NTRK1 fusion partner was LMNA gene present in 8 (57%) of 14 cases, followed by a TPM3-NTRK1 fusion identified in 3 (21%) cases (Table 1) . One of these cases were also validated by
Archer DX, showing an in-frame fusion between TPM3 exon 8 and NTRK1 exon10, preserving the kinase domain (Supporting Information, Figure S1 ). Only one case showed a TPR-NTRK1 gene fusion. In [12] [13] [14] In addition, BRAF gene rearrangements have been described recently in a subset of spindle cell sarcomas, morphologically resembling infantile fibrosarcomas. 4 In that study, we identified 3 children, ranging from 6 months to 16 years old, with tumors occurring in the abdominal cavity (1 retroperitoneum and 2 pelvic). The our cases, only 1 tumor was immunopositive for CD34, while S100
protein was not reported. 15 Although these tumors belong to the spectrum of spindle cell sarcomas with kinase fusion genes, we did not discern these growth patterns in any of the cases in this cohort.
A STRN-NTRK2 fusion variant was reported in one pediatric patient with soft tissue sarcoma, although the exact morphologic features remain unclear. 8, 16, 17 The case showed a transcript composed of STRN exon 15 fused to NTRK2 exon 4. We found an additional case in this study cohort displaying low cellularity and fibrotic stroma occur- MPNST in this context were proposed recently. 18 Importantly, lowgrade MPNST contains numerous S100-positive and SOX10-positive Schwann cells, while losing most of the intermixed CD34-positive fibroblastic framework stroma, which is typically retained in the preexistent neurofibroma component. In contrast, our study group with low-grade morphology showed co-expression of S100 and CD34, and consistently lacked SOX10 reactivity. Furthermore, none showed a neurofibroma component or had a history of NF1. On the other hand, high-grade MPNST can be sporadic, NF1-associated, or occur in the field of prior radiation. Up to 40% of high-grade MPNST focally express nerve sheath markers S100 and GFAP, and about 50% show focal nuclear SOX10 expression. 19 The large majority of high-grade MPNST shows diffuse loss of trimethylation of H3K27, which remains a useful diagnostic IHC marker. 20, 21 Notably, the NTRK1 and RAF1/ BRAF-rearranged tumors with increased cellularity and fascicular growth in this series were positive for S100 and CD34, negative for SOX10, and retained H3K27me3 expression. A somewhat controversial entity is the so-called "fibroblastic MPNST," a tumor that also shows co-expression of CD34 and S100. 22, 23 Mills et al. 22 cases, but lacks S100 expression. Moreover, nearly all SFT have a NAB2-STAT6 fusion 25 and STAT6 is a highly sensitive and specific IHC marker for SFT. 26, 27 Other bland fibroblastic spindle cell tumors with collagen bands and perivascular collagen deposits and diffuse CD34 expression include cellular angiofibroma, mammary-type myofibroblastoma, and spindle cell lipoma, three tumors which are histogenetically related, as they all have abnormalities in 13q14, leading to loss of Rb1. 28 All these CD34 fibroblastic tumors are S100 protein Furthermore, NTRK1 immunohistochemistry appears to be a sensitive method to select this subset of tumors with NTRK1 gene rearrangements.
